Financials BenevolentAI

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:35:17 2024-07-09 am EDT			5-day change	1st Jan Change
0.792 ^EUR	+11.55%		+68.51%	-26.67%

Jul. 03	BenevolentAI S.A. Announces CFO Changes	CI
Jun. 25	BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed into Portfolio	CI

Valuation

Fiscal Period: December	2022	2023	2024	2025	2026
Capitalization ¹	363.4	110	81.68	-	-
Enterprise Value (EV) ¹	233.2	37.11	56.1	-9.066	-13.53
P/E ratio	-2.06 x	-1.75 x	-4.04 x	-4.03 x	11.1 x
Yield	-	-	-	-	-
Capitalization / Revenue	34.4 x	15 x	2.9 x	3.61 x	1.87 x
EV / Revenue	22.1 x	5.06 x	1.99 x	-0.4 x	-0.31 x
EV / EBITDA	-2.55 x	-0.5 x	-1.28 x	0.22 x	1.55 x
EV / FCF	-2.99 x	-0.64 x	-1.08 x	0.24 x	-0.41 x
FCF Yield	-33.5%	-157%	-92.6%	416%	-243%
Price to Book	2.19 x	1.24 x	1.84 x	2.12 x	1.12 x
Nbr of stocks (in thousands)	117,489	117,489	121,940	-	-
Reference price ²	3.093	0.9364	0.6698	0.6698	0.6698
Announcement Date	3/16/23	3/14/24	-	-	-

¹GBP in Million²GBP

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net sales ¹	4.625	10.56	7.331	28.19	22.66	43.73
EBITDA ¹	-	-91.54	-74.69	-43.74	-42.09	-8.73
EBIT ¹	-	-197	-77.57	-45.63	-43.9	-9.021
Operating Margin	-	-1,865.85%	-1,058.15%	-161.88%	-193.78%	-20.63%
Earnings before Tax (EBT) ¹	-	-	-72.65	-35.04	-41.47	-40.12
Net income ¹	-86.48	-163.9	-63.32	-26.38	-30.06	1.254
Net margin	-1,869.92%	-1,552.35%	-863.69%	-93.6%	-132.7%	2.87%
EPS ²	-	-1.502	-0.5350	-0.1657	-0.1662	0.0601
Free Cash Flow ¹	-	-78.07	-58.23	-51.95	-37.69	32.9
FCF margin	-	-739.29%	-794.28%	-184.3%	-166.34%	75.23%
FCF Conversion (EBITDA)	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	2,622.56%
Dividend per Share	-	-	-	-	-	-
Announcement Date	3/15/22	3/16/23	3/14/24	-	-	-

¹GBP in Million²GBP

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2022 S2	2023 S1	2023 S2	2024 S1	2024 S2
Net sales ¹	5.717	5.297	2.034	8	56
EBITDA	41.5	-	-	-	-
EBIT ¹	-62.49	-40.56	-31.72	-26.86	20.7
Operating Margin	-1,093%	-765.72%	-1,559.64%	-335.8%	36.96%
Earnings before Tax (EBT)	-	-	-	-	-
Net income	-	-	-	-	-
Net margin	-	-	-	-	-
EPS	-	-0.3120	-0.2230	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	3/16/23	9/21/23	3/14/24	-	-

¹GBP in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-
Net Cash position ¹	-	130	72.9	25.6	90.7	95.2
Leverage (Debt/EBITDA)	-	-	-	-	-	-
Free Cash Flow ¹	-	-78.1	-58.2	-51.9	-37.7	32.9
ROE (net income / shareholders' equity)	-	-73.7%	-51%	-80.4%	-	55%
ROA (Net income/ Total Assets)	-	-56.9%	-	-	-	-
Assets ¹	-	288.3	-	-	-	-
Book Value Per Share ²	-	1.410	0.7600	0.3600	0.3200	0.6000
Cash Flow per Share	-	-	-	-	-	-
Capex ¹	-	1.16	1.11	2	2	2
Capex / Sales	-	10.97%	15.07%	7.1%	8.83%	4.57%
Announcement Date	3/15/22	3/16/23	3/14/24	-	-	-

¹GBP in Million²GBP

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for BenevolentAI

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6698 GBP

Average target price

1.241 GBP

Spread / Average Target

+85.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENEVOLENTAI	-26.67%	104M
MODERNA, INC.	+16.71%	44.48B
LONZA GROUP AG	+42.66%	40.57B
IQVIA HOLDINGS INC.	-7.92%	38.82B
ALNYLAM PHARMACEUTICALS, INC.	+33.09%	32.22B
CELLTRION, INC.	-7.10%	27.84B
ICON PUBLIC LIMITED COMPANY	+14.46%	26.79B
UNITED THERAPEUTICS CORPORATION	+46.73%	14.31B
MEDPACE HOLDINGS, INC.	+34.07%	12.7B
BIO-TECHNE CORPORATION	-7.61%	11.23B

Other Biotechnology & Medical Research